Yield of Serial Testing for Tuberculosis Exposure in Patients With Inflammatory Bowel Diseases: One Test is Not Enough

Clin Gastroenterol Hepatol. 2024 Feb;22(2):420-422.e2. doi: 10.1016/j.cgh.2023.06.003. Epub 2023 Jun 17.

Authors

Sean L Lapp¹, Meenakshi Bewtra², James D Lewis³; SPARC IBD Investigators

Collaborators

Affiliations

¹ Messiah University, New Holland, Pennsylvania.
² Division of Gastroenterology and Hepatology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
³ Division of Gastroenterology and Hepatology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.. Electronic address: [email protected].

PMID: 37331412
PMCID: PMC10725512 (available on 2025-02-01)
DOI: 10.1016/j.cgh.2023.06.003

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / adverse effects
Humans
Inflammatory Bowel Diseases* / chemically induced
Inflammatory Bowel Diseases* / diagnosis
Infliximab
Tuberculosis* / diagnosis

Substances

Infliximab
Antibodies, Monoclonal

Grants and funding